Anzeige
Erschienen in:
01.09.2009 | Retinal Disorders
Intravitreal bevacizumab for CNV-complicated tilted disk syndrome
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 9/2009
Einloggen, um Zugang zu erhaltenAbstract
Background
Tilted disc syndrome is a congenital anomaly characterized by an inferonasal “tilting” of the optic disc. We report three patients affected by macular neovascularisation-complicated tilted disk syndrome treated by intravitreal bevacizumab.
Methods
Three interventional case reports are hereby documented. Ophthalmic evaluations were registered, including monthly visual acuity examination, OCT and fluorescein angiography before and after consecutive intravitreal injection of 1.25 mg bevacizumab (0.05 ml, Avastin).
Results
All patients, aged more than 65 years, experienced decreased visual acuity after an observation period of 6 (two patients) and 3 months (one patient). Angiographic leakage with neuroretinal rarefaction and RPE/choriocapillary complex elevation at OCT remained persistent in two patients and reduced in one.
Conclusions
No benefit in terms of visual acuity was noted after intravitreal bevacizumab treatments. Larger studies should be conducted to confirm our small series observation.